SAN FRANCISCO--(BUSINESS WIRE)--Siris Medical, Inc., a company with headquarters in Silicon Valley and Boston that offers the only Artificial Intelligence (AI)-driven treatment decision-support system for use in radiation oncology, announced today that it has been awarded a contract with Northwestern Medicine (NM) Department of Radiation Oncology. NM will implement Siris’s InsightRTTM software as the primary treatment decision-support tool for the treatment of cancer patients.
According to a survey performed by the American Society of Therapeutic Radiation Oncology, insurance authorization can result in unnecessary treatment delays and impact patient care. Siris Medical's software platform streamlines the process needed to start treatment sooner.
Colin Carpenter PhD, President and CEO of Siris Medical adds: “We are excited to support NM in their innovative approach to ensure every patient receives the best cancer treatment. InsightRTTM uses artificial intelligence to fully leverage the clinical team’s expertise, accelerate the treatment decision process, and enable each patient to benefit from the best care possible to treat their disease.”
The QuickMatch module of InsightRT utilizes artificial intelligence and the rich experience of historical treatments to give clinicians insight into the best achievable treatment for each individual patient while eliminating the need for time consuming iterations that delay a patient's time to treatment. InsightRT is the only AI-driven radiotherapy treatment planning decision-support product on the market.
About Siris Medical
Siris Medical empowers clinicians to achieve efficient high-quality cancer radiation treatment decisions through its artificial intelligence platform, InsightRT, the first commercial decision-support system in radiation oncology. Please visit www.siris-medical.com for more information.